Who is sponsoring NCT05996432?

NCT05996432 is sponsored by Vanderbilt-Ingram Cancer Center.

What drugs are being tested in NCT05996432?

Interventions in NCT05996432: Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), 18F-fluoromisonidazole.

What condition does NCT05996432 study?

NCT05996432 studies Head and Neck Squamous Cell Carcinoma, Brain Metastases.

Is NCT05996432 still recruiting?

NCT05996432 is currently recruiting now. Last updated 23 September 2024.

Last reviewed 2024-09-23 · How we verify

NCT05996432

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Recruiting now EARLY_PHASE1 Last updated 23 September 2024

What this trial tests

EARLY_PHASE1 trial testing Magnetic Resonance Imaging (MRI) in Head and Neck Squamous Cell Carcinoma in 48 participants. Currently enrolling.

Timeline

17 May 2023

Primary endpoint
30 November 2026

31 May 2029

Quick facts

Lead sponsor	Vanderbilt-Ingram Cancer Center
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	48
Start date	17 May 2023
Primary completion	30 November 2026
Estimated completion	31 May 2029
Sites	1 location across United States

Drugs / interventions tested

Magnetic Resonance Imaging (MRI)
Positron Emission Tomography (PET) — full drug profile →
18F-fluoromisonidazole

Conditions studied

Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
Brain Metastases — all drugs for Brain Metastases →

Sponsor

Vanderbilt-Ingram Cancer Center — full company profile →

Who can join

18 and older, any sex, with Head and Neck Squamous Cell Carcinoma or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Imaging hypoxia for head and neck cancer: current status, challenges, and prospects.
Huang W, Li N, Zhu S, Zhang Y, et al · · 2025 · PMID 40860130 · DOI 10.7150/thno.112781

Verify or expand the search:

Other trials of Magnetic Resonance Imaging (MRI)

Trials testing the same drug.

NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting
NCT07346170 — Short Interval Postoperative Stereotactic Body Radiation Therapy (SBRT) After Surgical Intervention for Spine Metastases · NA · not yet recruiting
NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
NCT07185958 — Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy · not yet recruiting
NCT06492057 — Electromyostimulation (EMS) of Astronauts in Spaceflight (Easymotion-2) · NA · enrolling by invitation

Other recruiting trials for Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
NCT07254585 — SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting

Other Vanderbilt-Ingram Cancer Center trials

Trials by the same sponsor.

NCT06638398 — Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules · NA · active not recruiting
NCT06593106 — Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial · NA · recruiting
NCT06105801 — EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing · Phase 4 · recruiting
NCT06399640 — Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06016855 — Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05996432 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt-Ingram Cancer Center
Last refreshed: 23 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05996432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing